06 Jun 2026

CRC Research Update — June 06, 2026

Creator: The CRC Digest
Published: 2026-06-06T12:36:39Z

Today's colorectal cancer research highlights

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

CRC Research Update

DNA Methylation May Refine Anti-EGFR Treatment Selection Beyond Tumor Sidedness
Highly methylated colorectal cancer is consistently associated with inferior outcomes after anti-EGFR therapy, whereas low-methylated colorectal cancer appears relatively more sensitive, offering a biologically informative classifier beyond anatomic tumor location. (J Gastrointest Cancer)
ctDNA-Guided Anti-EGFR Rechallenge Shows Promise in Later-Line Metastatic CRC
Real-time molecular reassessment, particularly the absence of detectable RAS/BRAF mutations in circulating tumor DNA, helps identify patients who may benefit from anti-EGFR rechallenge after prior clinical benefit from EGFR blockade. (J Gastrointest Cancer)
Weighted Toxicity Score Analysis Compares Side Effects of Fruquintinib and Regorafenib
A weighted toxicity score analysis of the CORRECT and FRESCO-2 trials provides a systematic approach to summarize overall toxicity burden, helping patients and clinicians discuss treatment options in later-line metastatic colorectal cancer. (Clin Colorectal Cancer)
Methylation Biomarkers Show High Sensitivity for Colorectal Cancer Detection
The Cologuard assay demonstrates 92% sensitivity for detecting colorectal cancer, both outperforming traditional screening methods through DNA methylation detection. (J Cancer Res Ther)

🔬 Under 50 Spotlight

Research relevant to early-onset and younger CRC patients

Early-Onset CRC Represents Nearly 30% of Cases in Saudi Arabia
Of 1,365 patients with confirmed CRC, 406 (29.7%) had early-onset CRC (diagnosed before age 50), highlighting the growing burden of colorectal cancer in younger adults. (Saudi J Gastroenterol)
Young-Onset Rectal Cancer Projected to Reach 25% of Cases by 2030
Young-onset rectal cancer in adults under 50 is increasing worldwide and projected to represent up to 25% of rectal cancers by 2030, according to a tertiary center analysis. (Eur J Surg Oncol)

🧬 Biomarker Spotlight

Research by genetic subtype — KRAS, BRAF, MSI-H, HER2, and more

Novel SOS1 Inhibitors Show Potent Activity Against KRAS-Driven CRC
Highly potent and selective SOS1 inhibitors disrupted the SOS1-KRAS interaction, inhibited nucleotide exchange in wild-type and multiple KRAS variants, and showed submicromolar anti-proliferative activity in colorectal cancer cells. (J Med Chem)

Stay informed, stay hopeful — research continues to advance our understanding and treatment of colorectal cancer.

CRC Research Update

Subscribe to The CRC Digest